E-cigarettes Priority Setting Partnership

Our survey has now been launched click the link to respond:

Project Overview

Smoking is the leading cause of preventable death. Although not yet available on the NHS, electronic cigarettes are now the most popular aid to smoking cessation, with 37% of smokers using them for quit attempts, and approximately 2.6 million adults currently using them. However, as the popularity of electronic cigarettes have increased, so has the controversy associated with using them, and media scare stories may deter their use. The current evidence base is small and there is much we do not know.

The new Public Health England report (McNeil et al., 2018) contains lots of research questions that need addressing, relating to policy, nicotine, use in young people, use in adults, the use on smoking cessation and harm reduction, risks, safety and health risks, and pricing.

Project Description

This study aims to develop a Priority Setting Partnership between smokers/vapers and clinicians to identify and prioritise research questions relating to electronic cigarettes as a tool for smoking cessation and harm reduction.

Often, clinical research does not address the questions that are of greatest importance to patients, and their clinicians. The James Lind Alliance has developed methods for bringing patients and clinicians together to establish 'Priority Setting Partnerships (PSPs)’ that then identify and prioritise ‘uncertainties’, in order to inform publicly funded research.

All top ten priorities for the PSPs will be published on the JLA website, thus ensuring wide availability to government, academics, clinicians, research commissioners and funders to inform policy and practice.


Electronic Cigarettes Priority Setting Partnership
UK Centre for Tobacco and Alcohol Studies
Clinical Sciences Building, City Hospital
Nottingham, NG5 1PB

Email: Abby.Hunter@nottingham.ac.uk

Respond to our survey!

About Priority Setting Partnerships:

“This PSP has been a truly collaborative effort and everybody has had a voice. It has widened horizons and will shape clinical research for brain cancer patients and the people who look after them. This means that in future clinical research will be relevant, focused and cohesive. It's been a fabulous experience”

Helen Bulbeck, Director of brainstrust, about the Neuro-oncology PSP

Priority Setting Partnerships (PSPs) enable clinicians, patients and carers to work together to identify and prioritise uncertainties about the effects of treatments that could be answered by research. While the James Lind Alliance (JLA) facilitates these partnerships, the funding and organising is done by the PSP itself.

The JLA PSP process results in a Top 10. The aim of the Top 10 is to highlight important areas for research, but not necessarily to come up with the specific research questions. The Top 10 may include broader areas of importance where patients, carers and health professionals have agreed that there is a need for research. This informs researchers and research funders about priorities so that they can make their research as meaningful as possible to the people who need it.

JLA PSPs are characterised by following the method set out in the JLA Guidebook and are facilitated by a small team of JLA Advisers.

To ensure consistency, the JLA asks each PSP to conform to these underpinning principles:

Transparency of process
Balanced inclusion of patient, carer and clinician interests and perspectives
Exclusion of non-clinician researchers from voting (they may be involved in all other aspects of the process)
Exclusion of groups or organisations that have significant competing interests, for example pharmaceutical companies
A maintained audit trail from original submitted uncertainties, to final prioritised list.

To find out more about the areas in which PSPs have been identifying the uncertainties which really matter, please visit the PSPs section.

The James Lind Alliance (JLA) is a non-profit making initiative established in 2004.

Please share this page on twitter:

The JLA infrastructure is funded by the NIHR. Read their relationship statement here.